The FDA has approved FluMist, a nasal spray flu vaccine, for at-home use, offering a convenient and accessible option for individuals ages 18 to 49. This approval expands on the existing use of FluMist for children and adolescents ages 2 to 17, allowing their caregivers to administer the spray. The move comes after clinical trials demonstrated the safety and effectiveness of self-administering the vaccine, making flu protection more accessible for a wider population.